Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
UC Health Air Care & Mobile Care, Cincinnati, OH, USA.
Perfusion. 2024 May;39(4):752-758. doi: 10.1177/02676591231158273. Epub 2023 Feb 17.
Placement of percutaneous ventricular support devices such as an intraaortic balloon pump (IABP) or Abiomed Impella device can treat severe cardiogenic shock. Critical care transport medicine (CCTM) providers frequently manage patients supported by these devices during interfacility transfers, often using a helicopter air ambulance (HAA). An understanding of patient needs and management during transport is essential to informing crew configuration and training, and this study adds to the limited existing data on the HAA transport of this complex patient population.
We performed a retrospective chart review of all HAA transports of patients with an IABP ( = 38) or Impella ( = 11) device at a single CCTM program from 2016 to 2020. We evaluated transport times and composite variables for the frequency of adverse events, condition changes requiring critical care evaluation, and critical care interventions.
In this observational cohort, patients with an Impella device more frequently had an advanced airway and at least 1 vasopressor or inotrope active prior to transport. While flight times were similar, CCTM teams remained at referring facilities longer for patients with an Impella device (99 vs 68 minutes; = 0.0097). Compared to patients with an IABP, patients with an Impella device more frequently had a condition change requiring critical care evaluation (100% vs 42%; = 0.0005) and more frequently received critical care interventions (100% vs 53%; = 0.0037). Adverse events were uncommon and did not differ for patients with an Impella device compared to an IABP (27% vs 11%; = 0.178).
Patients requiring mechanical circulatory support with IABP and Impella devices frequently require critical care management during transport. Clinicians should ensure the CCTM team has appropriate staffing, training, and resources to meet the critical care needs of these high acuity patients.
经皮心室支持装置(如主动脉内球囊泵[IABP]或 Abiomed Impella 装置)的放置可治疗严重的心源性休克。重症监护转运医学(CCTM)提供者在机构间转运期间经常管理这些设备支持的患者,通常使用直升机空中救护(HAA)。了解转运过程中的患者需求和管理对于告知机组人员配置和培训至关重要,本研究增加了现有关于该复杂患者群体使用 HAA 转运的有限数据。
我们对 2016 年至 2020 年期间,在单一 CCTM 计划中使用 HAA 转运 IABP(=38)或 Impella(=11)装置的患者进行了回顾性图表审查。我们评估了转运时间和复合变量,以评估不良事件的发生频率、需要进行重症监护评估的病情变化以及重症监护干预。
在这项观察性队列研究中,携带 Impella 装置的患者在转运前更频繁地使用高级气道和至少一种血管加压药或正性肌力药。虽然飞行时间相似,但 CCTM 团队在携带 Impella 装置的患者的转诊机构停留时间更长(99 分钟对 68 分钟;=0.0097)。与携带 IABP 的患者相比,携带 Impella 装置的患者更频繁地出现需要进行重症监护评估的病情变化(100%对 42%;=0.0005),并且更频繁地接受重症监护干预(100%对 53%;=0.0037)。不良事件很少见,携带 Impella 装置的患者与携带 IABP 的患者相比没有差异(27%对 11%;=0.178)。
接受 IABP 和 Impella 装置机械循环支持的患者在转运过程中经常需要重症监护管理。临床医生应确保 CCTM 团队有适当的人员配备、培训和资源,以满足这些高重症患者的重症监护需求。